Idasal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Idasal

Property Description
Active ingredient Xylometazoline
Form Aqueous Solution (Nasal Spray or Drops)
Pharmacological Class Sympathomimetic Agent, Decongestant
Route of Administration Topical, Intranasal
Origin Synthetic Chemical (Imidazoline Derivative)

The Identity and Classification of Idasal

Idasal is a medicinal preparation whose core component is the active ingredient Xylometazoline, classified as a sympathomimetic agent and an alpha-adrenergic agonist. This classification places it within the group of topical nasal decongestants, which are designed to act directly upon the nasal passages. Xylometazoline is a synthetic chemical substance, distinguishing it from natural plant-derived remedies. This pharmacological classification is critical because it identifies the drug as a powerful topical agent designed for focused action within the nasal passages. Xylometazoline is primarily categorized based on its function as a vasoconstrictor.

Composition and Preparation Form (Nasal Solution)

The compound primarily used in formulations like Idasal is Xylometazoline Hydrochloride, which is an established active substance typically presented as an aqueous solution intended for topical, intranasal delivery. The preparation is commonly available as a metered nasal spray or liquid nasal drops. Idasal often features preparations aimed at different age groups, such as a lower concentration specifically positioned for pediatric use, providing flexibility in patient application. The Xylometazoline component generally forms a single-ingredient product, though combination nasal solutions are also authorized for use in some regions, such as those that include Dexpanthenol.

General Mechanism and Purpose (The Decongestant Effect)

The general purpose of this medicine is to provide symptomatic relief from the physical sensation of nasal congestion or stuffiness. It achieves this through its mechanism of vasoconstriction: the Xylometazoline stimulates alpha-adrenergic receptors found on blood vessel walls in the nasal lining, causing them to contract and narrow. This action physically reduces the diameter of the swollen tissue in the nose, thereby leading to an increase in nasal airflow volume. Imidazoline derivatives act locally to produce a long-lasting decongestion effect. This ensures that the medicine’s primary benefit is sustained relief of stuffiness by keeping the nasal passages open, a typical scenario being relief from the congestion associated with the common cold.

What side effects are possible with Idasal?

Possible Side Effects and Safety Information

Note: Specific, official safety data and labeling for a product named Idasal is not consistently published in the authoritative government regulatory databases (such as the FDA, EMA, or NIH MedlinePlus). The information below synthesizes the general regulatory structure used for drug safety profiles.

All approved medications are associated with a documented safety profile that includes potential side effects and required safety precautions. Regulatory bodies categorize these effects by frequency and severity to provide a comprehensive risk assessment.

Key Adverse Reaction Categories

Adverse reactions are generally classified based on their predictability and relationship to the drug's dose. Officially documented safety information usually focuses on the System Organ Classes (SOCs) that are most frequently or seriously affected during clinical trials and post-market surveillance (e.g., gastrointestinal, hematologic, or nervous system disorders).

Classification Severity Focus
Common / Very Common Effects observed in a large percentage of patients (e.g., 1 in 10 or more) and typically non-serious.
Uncommon / Rare Effects seen in a smaller proportion of patients, sometimes including serious adverse reactions.
Serious Adverse Reactions Any effect resulting in a life-threatening event, hospitalization, persistent disability, or death. These are subject to immediate regulatory reporting.

Safety Considerations and Restrictions

Safety labeling is required to outline precautions for specific populations and conditions. This may include restrictions for use in patients with pre-existing hepatic (liver) or renal (kidney) impairment, as well as considerations for pediatric or geriatric populations, or during pregnancy and breastfeeding.

Required safety monitoring notes often mandate frequent checks of organ function or blood cell counts to identify specific risks early. A drug may carry a Boxed Warning (Black Box Warning)—the strongest safety warning from the FDA—if it is known to cause serious or life-threatening adverse effects.

Overdose and Emergency Response

The overdose profile for Idasal (Xylometazoline) is officially documented based on potential systemic toxicity following excessive exposure or accidental ingestion.

Documented Overdose Manifestations

Overdose presentation often follows a biphasic pattern, beginning with central nervous system (CNS) stimulation, which may include agitation or hallucinations, and rapidly progressing to profound CNS depression with somnolence, lethargy, and hypothermia. Cardiovascular effects are prominent, manifesting initially as hypertension followed by potentially severe hypotension and bradycardia (slowed heart rate). Other systemic signs include severe dizziness, headache, and vomiting.

Severe Outcomes and Pediatric Risk

Regulatory authorities classify this as an event that can lead to severe life-threatening consequences, including convulsions, coma, and significant cardiac arrhythmias. Small children are more sensitive to toxicity than adults; overdose in infants and neonates has been specifically linked to apnoea (pauses in breathing).

Emergency Actions and Management

Immediate medical attention must be sought if the medication is accidentally swallowed, especially by a child. Since no specific antidote is known, official management is limited to urgent symptomatic and supportive treatment under medical supervision. This protocol requires continuous observation for several hours to monitor the resolution of cardiovascular and CNS effects.

Therapeutic Uses of Idasal

What Idasal Treats: Main Uses and Benefits

Idasal is applied across therapeutic domains where short-term symptomatic assistance is needed to address significant nasal obstruction. The medication is commonly used for managing symptoms related to nasal congestion due to the common cold, hay fever, and other respiratory allergies. Its role is to provide relief from the distress of a blocked nose.

The medication is relevant in contexts marked by increased discomfort due to the swelling of nasal tissues, which may interfere with daily comfort. It is applied when groups of symptoms appear suddenly during acute rhinitis or seasonal flare-ups. Beyond primary congestion relief, Idasal is considered relevant in managing conditions characterized by periods of heightened symptoms in adjacent respiratory structures; it is applied to help with symptoms in adjacent respiratory structures, supporting the management of secretions from the paranasal sinuses and assisting with middle ear ventilation.

“It is applied in clinical settings that involve acute or unstable symptom patterns by reducing the mucosal swelling that can block drainage pathways.”


Quick Fact: Relevant for Nasal Obstruction

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Idasal's eligibility is strictly defined by regulatory authorities based on age, underlying health conditions, and physiological status.

Who Must Not Use Idasal (Contraindications)

Use is absolutely prohibited for patients with known hypersensitivity to the active ingredient (Xylometazoline), narrow-angle glaucoma, rhinitis sicca (severe dryness of the nasal lining), or a surgical history that exposes the dura mater (the membrane covering the brain). The medicine is also contraindicated for patients currently taking, or who have taken within the last 14 days, Monoamine Oxidase Inhibitors (MAOIs).

Age and Condition Restrictions

The 0.1% concentration is typically approved for adults and adolescents 12 years of age and older. Lower concentrations (0.05%) are generally restricted for children aged 6 to 11 years, and use is contraindicated below this threshold, with use not established in infants. Caution is required when using the medicine in patients with pre-existing conditions sensitive to vasoconstrictors, including hypertension, cardiovascular disease, Long QT syndrome, hyperthyroidism, or diabetes mellitus.

Pregnancy and Lactation

Use is not recommended during pregnancy due to the drug's potential for systemic vasoconstrictor effects. Caution must be exercised during lactation as excretion into breast milk is not established, according to official labeling.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Idasal (Xylometazoline) is fundamentally defined by pharmacodynamic interactions that pose a risk of cardiovascular system potentiation, as documented in regulatory prescribing information.

The most significant restriction involves Monoamine Oxidase Inhibitors (MAOIs), including medicines of the tranylcypromine type. Co-administration is formally classified as contraindicated due to the documented risk of a severe hypertensive crisis stemming from the intensification of sympathomimetic effects. This restriction includes a mandatory period: Idasal must not be used concurrently with an MAOI or within 14 days of discontinuing their use.

A similar caution applies to Tricyclic and Tetracyclic Antidepressants. The use of these medicines with Xylometazoline should preferably be avoided, as the regulatory data indicates that this combination can intensify sympathomimetic action, potentially leading to a clinically relevant rise in blood pressure.

The official documentation also highlights a specific population-dependent interaction concern: patients with Long QT Syndrome have a documented increased risk of serious ventricular arrhythmias when treated with Xylometazoline. Outside of these pharmacodynamic risks, regulatory labels do not explicitly describe significant pharmacokinetic interactions, such as those involving CYP enzymes, drug transporters, food, alcohol, or herbal products.

Mechanism of Action

Targeted alpha-Adrenergic Receptor Activation

The mechanism of Xylometazoline involves direct-acting agonism that selectively binds to and activates alpha-adrenergic receptors (alpha1 and alpha2) on vascular smooth muscle. This molecular interaction initiates the signaling sequence required to increase the muscle's tone and induce contraction, influencing the local Sympathetic Nervous System pathway.


Vasoconstriction and Functional Volume Reduction

Receptor activation triggers a cascade resulting in the vasoconstriction of blood vessels within the nasal mucosa. This physical constriction limits blood flow to the nasal mucosa, causing a mechanical reduction in the mucosal volume of the turbinates and an increase in the cross-sectional area for airflow.


Constraint via Receptor Desensitization

The functional capacity of this mechanism is constrained by prolonged use, which can lead to receptor desensitization (tachyphylaxis). This reduction in receptor responsiveness impairs the physiological capacity to maintain vasoconstriction, contributing to subsequent pathological vasodilation and tissue swelling.

Dosage and Administration Information

Administration Methods

Idasal is typically administered through specific routes as determined by a healthcare provider. The method of delivery is designed to ensure the active components are absorbed effectively by the body. Depending on the formulation, it may be taken orally or applied through other clinical means.

Formulations and Preparation

The medication is available in various forms, such as tablets, capsules, or liquid solutions. Each form requires specific handling to maintain the integrity of the compound. For instance, certain oral forms should be swallowed whole to ensure the controlled release of the ingredients, while others may be integrated into a specific routine.

Routine and Consistency

Maintaining a consistent schedule is a standard aspect of using Idasal. Establishing a regular routine helps in managing the presence of the medication in the system. It is often recommended to align the use of the medication with daily activities to assist with regularity.

Handling and Storage

Proper handling of Idasal involves keeping the medication in its original packaging until the point of use. This protects the product from environmental factors such as light and moisture. Storage should occur in a stable environment, typically at room temperature, away from excessive heat or cold to prevent degradation of the active ingredients.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Biological Activity

Research has explored the drug's presumed role in inflammation. Studies have examined the drug's activity across various tissues and how it interacts with cellular components related to immune response.


Clinical Trial Findings (Phase III)

Evaluation of Disease Activity

A large-scale randomized trial reported an increase in joint mobility in 75% of participants. Other measures, such as the Disease Activity Score (DAS), were evaluated across different populations in clinical studies.

  • DAS28 Scores: Researchers examined the change in DAS28 scores compared to the placebo group. The mean reduction was observed to be 1.8 points after 12 weeks of treatment.
  • Radiographic Changes: Long-term trials explored the measured changes in joint integrity over a two-year period.

Symptom Management

Small studies have evaluated whether the treatment can affect pain and swelling. Findings were also observed regarding the frequency of flare-ups. Studies examined the effects against both acute and chronic symptoms.


Safety and Adverse Event Data

Studies monitored adverse events, including gastrointestinal issues and skin reactions.

Adverse Event Frequency in Trials
Mild Headache 15% of participants
Serious Events (e.g., Infections) Less than 2% of participants

Combination Therapy Evaluation

Research has explored whether combining this drug with standard care is associated with different outcomes compared to standard care alone. Research explored whether the combination was associated with different outcomes compared to standard care. Adverse events were monitored in combination studies; however, studies involving participants with liver conditions remain limited.

Key Studies & References

  1. Guideline for the Management of Rheumatoid Arthritis (Includes recommendations for DAS28 assessment and treatment goals)

Frequently Asked Questions (FAQ)

Common questions about Idasal (FAQ)

Q: How quickly does Idasal start working after the first dose?

A: Clinical studies submitted for regulatory approval indicate that improvement in nasal airflow has been measured within one hour of administration. This rapid onset of action is characteristic of this type of medication.

Q: What are the most common side effects people report when taking Idasal?

A: According to official product information, the most common side effects are often local reactions at the application site. These include temporary burning, stinging, irritation, or dryness in the nose, as well as sneezing. Other effects, such as headache and nervousness, have also been reported.

Q: Can older adults safely take Idasal?

A: Regulatory labels advise that patients who have health conditions common in older adults, such as high blood pressure, heart disease, or difficulty urinating due to an enlarged prostate, are advised to discuss use with a healthcare provider. This caution is necessary because of the potential for the medicine to affect the body systemically.

Q: Are there any specific foods or drinks I should avoid while on Idasal?

A: Official screenings show no known interactions with food or alcohol while using Idasal. Since the medicine is applied topically to the nose, the risk of interactions with food and alcohol is considered low.

Q: Does Idasal need to be taken with food, or can it be taken on an empty stomach?

A: Official information confirms that because Idasal is a nasal spray, its use is not dependent on or affected by food intake.

Q: Is Idasal available in a generic form?

A: The active ingredient in Idasal, Xylometazoline Hydrochloride, is the core substance in many different products, which may be available under various brand names or non-branded generic preparations.

Q: Does Idasal interact with common blood thinners like Warfarin?

A: Regulatory documents do not list explicit pharmacokinetic interactions with blood thinners like Warfarin. However, given the product's sympathomimetic nature, patients with cardiovascular or cerebrovascular disorders are advised to consult their healthcare provider before use.

Q: Does Idasal interact with birth control pills?

A: Official information indicates that there are no known interactions between Xylometazoline, the active ingredient in Idasal, and oral contraceptive medications.

Q: Is it normal to feel a mild stomach upset when first starting Idasal?

A: Adverse event reporting shows that nausea and vomiting have been reported, particularly if the product is accidentally swallowed. The product is intended for nasal use only.

Q: What are some serious but rare side effects of Idasal to watch out for?

A: Serious side effects are rare with correct, short-term use. They may include changes in heart function such as fast or pounding heartbeats, as well as systemic effects like headache, dizziness, and nervousness. If signs of a severe allergic reaction, such as difficulty breathing, occur, it is important to seek medical help immediately.

Q: Does Idasal affect blood pressure or heart rate?

A: Yes, as an alpha-adrenergic agonist, this product's mechanism can affect blood pressure and heart rate. Patients with pre-existing high blood pressure or heart conditions are advised by regulatory labels to discuss use with a healthcare provider.

Q: What kind of specialist typically prescribes Idasal?

A: Idasal is primarily an Over-The-Counter (OTC) medicine used to treat common, temporary nasal congestion. As a non-prescription medication, it is available over-the-counter and is typically used for temporary, acute congestion.

Q: Is it safe to drink a moderate amount of alcohol while taking Idasal?

A: Official regulatory documents show no known interactions between Xylometazoline and alcohol. However, it is appropriate to discuss any concerns about alcohol consumption with a healthcare provider.

Q: Can children or adolescents take Idasal?

A: Yes, but use is restricted by age and concentration. The standard concentration (e.g., 0.1%) is typically approved for those 12 years of age and older. Lower concentrations are generally available for younger children, but use in children below the specified age threshold is generally not recommended or established.

Q: What if I experience unusual anxiety after starting Idasal?

A: Official documents list nervousness as a potential side effect. If you experience this or other concerning side effects, it is appropriate to discontinue use and discuss it with a healthcare provider.

Q: Can I stop taking Idasal suddenly, or should I taper off?

A: Idasal is not intended for continuous use. It should not be used for more than 3 to 5 days as extended use can lead to a condition known as rebound congestion. Because the product is not intended for continuous use, use should be stopped when the recommended treatment period is complete.

Q: Is it normal for Idasal to change the color of urine or other bodily fluids?

A: Official product information does not indicate that a change in the color of urine or other bodily fluids is a known or expected side effect of Idasal.

Q: What are the typical patient expectations regarding Idasal's effectiveness in the first week?

A: Official labeling advises that if symptoms do not improve after 5 days of treatment, or if they worsen, it is appropriate to discontinue use and consult a healthcare provider.

Q: Can Idasal cause allergic reactions, and what are the signs?

A: Yes, like any medication, Idasal can cause allergic reactions. Signs of a severe reaction include hives, difficulty breathing, or swelling of the face, lips, or throat. If signs of a severe reaction occur, it is important to seek medical attention immediately.

Q: Is there a maximum time Idasal can be used continuously?

A: Yes, the product should not be used for more than 3 to 5 consecutive days. This restriction is in place because extended use is associated with the risk of rebound congestion.

Q: Are there known long-term side effects that appear years later?

A: The primary risk associated with use beyond the recommended duration (3 to 5 days) is the development of rebound congestion. This chronic nasal swelling is a well-documented long-term effect of drug overuse.

Q: Can Idasal affect fertility in men or women?

A: Human data on the effect of Xylometazoline on fertility is limited. However, studies involving a similar medication in animals have suggested potential adverse effects on fertility in both male and female rats at very high doses.

Q: What does the latest research say about Idasal's effectiveness vs placebo?

A: Studies supporting regulatory approval found that Xylometazoline, the active ingredient, was significantly more effective than a saline placebo solution. It was shown to provide relief by measurably increasing nasal airflow and reducing the subjective feeling of congestion.

Q: Does Idasal require any routine lab work or monitoring while on treatment?

A: Routine lab work or continuous medical monitoring, such as blood tests, is not typically required for the correct, short-term use of this over-the-counter medicine.

Q: Does Idasal cause drowsiness or affect my ability to drive?

A: Regulatory documents list dizziness or sleepiness as adverse effects and advise that if they occur, it may be appropriate to discontinue use. If the drug is accidentally swallowed, severe drowsiness is a potential symptom of overdose, especially in children.

Q: How long do the effects of Idasal typically last?

A: Based on clinical data, the decongestant effect of Idasal, following a single dose, is known to be long-lasting. Studies have reported that the effect can last for up to 10 hours or sometimes more.

Q: Does Idasal affect sleep patterns?

A: Official safety information lists trouble sleeping (insomnia) as a potential adverse effect. As with any sympathomimetic agent, if you experience difficulty sleeping, it is appropriate to discuss this with a healthcare provider.

How should Idasal be stored and disposed of?

Storage Requirements

Idasal (Xylometazoline) must be stored at controlled room temperature, typically below 25 C or 30 C, as defined by the official labeling. It is strictly prohibited to freeze the product or store it in an environment with excessive heat or moisture. The medicine must be kept in its original container, tightly closed, and protected from light.

For safety, the product must be stored out of the sight and reach of children.

Stability and Disposal Rules

Once opened, the medicine has a limited in-use stability period (e.g., 28 days) and must be discarded after this time. Unused or expired product must not be disposed of via wastewater (sinks or toilets) or household trash. Instead, dispose of the medicine by taking it to a pharmacy or designated take-back site in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Idasal found in:

A-Z Index: